Vasilios G Bournas, DO | |
1032 E Sumner St, Hartford, WI 53027-1608 | |
(262) 673-2300 | |
Not Available |
Full Name | Vasilios G Bournas |
---|---|
Gender | Male |
Speciality | Emergency Medicine |
Experience | 14 Years |
Location | 1032 E Sumner St, Hartford, Wisconsin |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1447575642 | NPI | - | NPPES |
100030222 | Medicaid | WI |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207P00000X | Emergency Medicine | 60856 (Wisconsin) | Primary |
207P00000X | Emergency Medicine | 036.132065 (Illinois) | Secondary |
Facility Name | Location | Facility Type |
---|---|---|
Ascension All Saints Hospital | Racine, WI | Hospital |
Ascension Se Wisconsin Hospital - St Joseph Campus | Milwaukee, WI | Hospital |
Vernon Memorial Hospital | Viroqua, WI | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Emergency Medicine Specialists Sc | 8729975461 | 195 |
News Archive
A Biodesign team of researchers, led by Randall Nelson, PhD, has received a new five-year, $3.1 million award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health. Their goal is to discover and validate telltale molecular signs to learn how to predict who will develop the disease long before any symptoms of diabetes appear.
Enzon Pharmaceuticals, Inc. today announced its financial results for the second quarter of 2010. For the second quarter of 2010, Enzon reported a loss from continuing operations of $5.4 million or $0.09 per diluted share, as compared to a loss of $19.7 million or $0.43 per diluted share for the second quarter of 2009.
A new study from Japan investigated various prognostic indicators, including clinico-pathological and pre-operative hematological factors to develop a novel prognostic factors-based risk stratification model for disease-specific survival in bladder cancer patients treated with radical cystectomy.
Medication, angioplasty or surgery? For some heart disease patients, there's no clear-cut choice. The key to getting the best care is to follow your individual doctor's advice, new research shows.
› Verified 2 days ago
Entity Name | Emergency Medicine Specialists Sc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1568413524 PECOS PAC ID: 8729975461 Enrollment ID: O20040228000032 |
News Archive
A Biodesign team of researchers, led by Randall Nelson, PhD, has received a new five-year, $3.1 million award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health. Their goal is to discover and validate telltale molecular signs to learn how to predict who will develop the disease long before any symptoms of diabetes appear.
Enzon Pharmaceuticals, Inc. today announced its financial results for the second quarter of 2010. For the second quarter of 2010, Enzon reported a loss from continuing operations of $5.4 million or $0.09 per diluted share, as compared to a loss of $19.7 million or $0.43 per diluted share for the second quarter of 2009.
A new study from Japan investigated various prognostic indicators, including clinico-pathological and pre-operative hematological factors to develop a novel prognostic factors-based risk stratification model for disease-specific survival in bladder cancer patients treated with radical cystectomy.
Medication, angioplasty or surgery? For some heart disease patients, there's no clear-cut choice. The key to getting the best care is to follow your individual doctor's advice, new research shows.
› Verified 2 days ago
Entity Name | Ihc-sacred Heart Emergency Physicians Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1992847826 PECOS PAC ID: 7113023391 Enrollment ID: O20070504000049 |
News Archive
A Biodesign team of researchers, led by Randall Nelson, PhD, has received a new five-year, $3.1 million award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health. Their goal is to discover and validate telltale molecular signs to learn how to predict who will develop the disease long before any symptoms of diabetes appear.
Enzon Pharmaceuticals, Inc. today announced its financial results for the second quarter of 2010. For the second quarter of 2010, Enzon reported a loss from continuing operations of $5.4 million or $0.09 per diluted share, as compared to a loss of $19.7 million or $0.43 per diluted share for the second quarter of 2009.
A new study from Japan investigated various prognostic indicators, including clinico-pathological and pre-operative hematological factors to develop a novel prognostic factors-based risk stratification model for disease-specific survival in bladder cancer patients treated with radical cystectomy.
Medication, angioplasty or surgery? For some heart disease patients, there's no clear-cut choice. The key to getting the best care is to follow your individual doctor's advice, new research shows.
› Verified 2 days ago
Mailing Address | Practice Location Address |
---|---|
Vasilios G Bournas, DO 6632 N Kolmar Ave, Lincolnwood, IL 60712-3332 Ph: (630) 532-2841 | Vasilios G Bournas, DO 1032 E Sumner St, Hartford, WI 53027-1608 Ph: (262) 673-2300 |
News Archive
A Biodesign team of researchers, led by Randall Nelson, PhD, has received a new five-year, $3.1 million award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health. Their goal is to discover and validate telltale molecular signs to learn how to predict who will develop the disease long before any symptoms of diabetes appear.
Enzon Pharmaceuticals, Inc. today announced its financial results for the second quarter of 2010. For the second quarter of 2010, Enzon reported a loss from continuing operations of $5.4 million or $0.09 per diluted share, as compared to a loss of $19.7 million or $0.43 per diluted share for the second quarter of 2009.
A new study from Japan investigated various prognostic indicators, including clinico-pathological and pre-operative hematological factors to develop a novel prognostic factors-based risk stratification model for disease-specific survival in bladder cancer patients treated with radical cystectomy.
Medication, angioplasty or surgery? For some heart disease patients, there's no clear-cut choice. The key to getting the best care is to follow your individual doctor's advice, new research shows.
› Verified 2 days ago
Julie Faber, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1032 E Sumner St, Hartford, WI 53027 Phone: 262-673-2300 | |
Benjamin J Krause, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1032 E Sumner St, Hartford, WI 53027 Phone: 262-670-4300 | |
James J Kambol, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1032 E Sumner St, Hartford, WI 53027 Phone: 262-673-2300 Fax: 262-670-7620 | |
Dr. Antony V George, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1032 E Sumner St, Hartford, WI 53027 Phone: 262-673-2300 | |
Mamta M Pandey, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1032 E Sumner St, Hartford, WI 53027 Phone: 262-670-7240 | |
Aurora M Lybeck, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1032 E Sumner St, Hartford, WI 53027 Phone: 262-376-2300 | |
Dr. Sarah Simcha Silver, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1032 E Sumner St, Hartford, WI 53027 Phone: 262-673-2300 |